Insys Therapeutics (INSY) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
Insys Therapeutics (NASDAQ:INSY) issued its quarterly earnings data on Tuesday. The company reported $0.23 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.28 by $0.05, Analyst Ratings News reports. The company had revenue of $41.60 million for the quarter, compared to the consensus estimate of $45.63 million.
Shares of Insys Therapeutics (NASDAQ:INSY) opened at 27.63 on Tuesday. Insys Therapeutics has a 52-week low of $6.20 and a 52-week high of $57.9133. The stock has a 50-day moving average of $39.51 and a 200-day moving average of $35.44. The company has a market cap of $923.1 million and a P/E ratio of 23.23.
Several analysts have recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of Insys Therapeutics from $46.00 to $88.00 in a research note on Wednesday, March 5th. Analysts at JMP Securities raised their price target on shares of Insys Therapeutics from $50.00 to $99.00 in a research note on Wednesday, March 5th. They now have an “outperform” rating on the stock.
Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.